As the company is 'blind' to the results it is difficult to see the company saying much more than it has in the past as each group of patients finish the procedure. The last thing LCT management should be focussed on is the SP. I would have thought that Mr Market will take care of the SP when results are advised to the market. A positive outcome at the end of the 'blind' test and its off to Disneyland for shareholders, a negative outcome (which based on current available news seems a low chance) would see the SP back in the 3-5c range. The only question shareholders need to be asking themselves is what level of risk (and potential loss) am I prepared to accept in return for the potential upside of a positive outcome in October.
LCT Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)